1 research outputs found
CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis
AimsCD30 expression by bone marrow (BM) mast cells (MC) has been
reported recently in systemic mastocytosis (SM) patients. The aim of
this study was to investigate the potential diagnostic and prognostic
value of CD30 expression in SM as assessed by multiparameter flow
cytometry.
Methods and resultsA total of 163 consecutive BM samples corresponding
to 142 SM patients and 21 non-mastocytosis cases were studied. CD30 was
positive in most SM patients (80\%), but in only one non-mastocytosis
case (4.8\%). When combined with CD25, CD30 contributed to an improved
accuracy over that of CD25 alone (98\% versus 93\%) mainly because most
(eight of nine) of the well-differentiated SM (WDSM), who lacked CD25,
were CD30(+). Similar levels of expression of CD30 were observed among
all different subgroups of SM except mast cell leukaemia; among indolent
SM (ISM) patients, no significant association was observed between the
levels of CD30 expression and other clinical and biological features of
the disease.
ConclusionsThe increased expression of CD30 associated with absence of
CD25 contributes to the diagnosis of WDSM and its distinction from other
subtypes of SM. By contrast, CD30 expression did not contribute either
to prognostic stratification of ISM or to the differential diagnosis
between ISM and aggressive SM cases